Tadakatsu Hayase

This inventor holds 9 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Basilea Pharmaceutica Ag, Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche Ag. Active years: 2001-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tadakatsu Hayase. Retrieved from https://idiyas.com/inventor/tadakatsu-hayase

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 3)

% Patents Active = 77.8

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 10.2

ph-index = 4

Forward Citations = 44(Granted Patents)

Location History:

Chigasaki, JP (2001 - 2008)
Kita-ku, JP (2008)
Kanagawa, JP (2013 - 2015)

Company Filing History:

4 out of 72

Basilea Pharmaceutica Ag

patents

4 out of 987

Chugai Seiyaku Kabushiki Kaisha

patents

2 out of 181

F. Hoffmann-La Roche Ag

patents

4. 1 out of 2

Basilea Pharmaceutica Ag, a Swiss Company

patents

where one patent can have more than one assignee

Years Active: 2001-2015

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9102692 - Aminopyrazole derivative (2015-08-11),

2. 8829199 - Aminopyrazole derivative (2014-09-09),

3. 8362236 - Macrocyclic compound (2013-01-29),

4. 7459561 - N-substituted carbamoyloxyalkyl-azolium derivatives (2008-12-02),

5. 7378446 - Compound having anti-HCV activity and process for producing the same (2008-05-27),

6. 7189858 - N-phenyl substituted carbamoyloxyalkyl-azolium derivatives (2007-03-13),

7. 7151182 - Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives (2006-12-19),

8. 6812238 - N-substituted carbamoyloxyalkyl-azolium derivatives (2004-11-02),

9. 6300353 - Azoles for treatment of fungal infections (2001-10-09),

Title: The Innovative Contributions of Tadakatsu Hayase

Introduction

Tadakatsu Hayase is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. With a total of 9 patents to his name, Hayase's work has the potential to impact the lives of many patients.

Latest Patents

Among his latest patents is an aminopyrazole derivative that presents a method for treating cancer. This method involves administering a pharmaceutically effective amount of a composition containing a compound represented by a specific formula. The formula includes various groups that can be tailored to enhance the effectiveness of the treatment. Another notable patent involves a compound that can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues, showcasing his innovative approach to tackling complex medical challenges.

Career Highlights

Throughout his career, Hayase has worked with reputable companies such as Basilea Pharmaceutica AG and Chugai Seiyaku Kabushiki Kaisha. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Hayase has collaborated with notable colleagues, including Nobuo Shimma and Jun Ohwada. These partnerships have likely enriched his research and development efforts, leading to the successful creation of his patented innovations.

Conclusion

Tadakatsu Hayase's contributions to cancer treatment through his innovative patents highlight his dedication to improving healthcare. His work continues to inspire advancements in the pharmaceutical field, making a lasting impact on patient care.

Profile summary based on public USPTO records.